Alnylam (ALNY) and Cubist (CBST) Announce Data From Phase II Study of ALN-RSV01 in Lung Transplant Patients
More News related to ALNY
- Alnylam to Webcast R&D Day on Thursday, November 12, 2009
- Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) Meeting
- Alnylam Pharma (ALNY) Posts Q3 adj.-Loss of $0.23, Beats by 1c
- Alnylam Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Alnylam Pharma (ALNY) Advances to RNAi Landmark Stage of Landmark Roche Alliance
More News related to CBST
- The Boston Globe names Cubist to Globe 100's Top Places to Work '09
- Cubist Pharmaceuticals to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Oppenheimer Upgrades Cubist Pharmaceuticals (CBST) to Perform
- Hydra Biosciences and Cubist Form Collaboration to Develop Novel Ion Channel Drugs for Pain Management
- Cubist Pharmaceuticals (CBST) Tops Q3 EPS Views
More News related to FDA
- After-Hours Movers 11/10: BITS, GSB, OCNF, HOO Higher; TGIC, MCZ, STV, MBLX, EM Lower
- Trading Radar for 11/11: Macy's (M), Progressive (PGR), Advanced Auto Parts (AAP), Computer Sciences (CSC) Report
- Unusual 11 Mid-Day Movers 11/10: UPG, CSII, SGK, MEDQ Higher; RHIE, OPXT, PRKR, MBI Lower
- Notable ETF Movers: PGM, XLV, SMH Up; UNG, KRE, FXI, AGQ, XME Down
- Notable Analyst Rating Changes 11/10: ADBE, ANN, FRPT, RAX Upgraded; ALU, CPST, PIKE, TRW Downgraded
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) reported preliminary data from their Phase II study of ALN-RSV01, an RNAi therapeutic in development for the treatment of respiratory syncytial virus (RSV) infection.
Overall, the study achieved its primary objective of demonstrating safety and tolerability of ALN-RSV01 over 30 days post treatment. In particular, there were no drug-related serious adverse events or discontinuations, and there were no clinically significant differences in the overall adverse event profile between ALN-RSV01 and placebo. Further, patients treated with ALN-RSV01 showed no significant increases in plasma cytokine levels and showed no changes in lung function post-dosing as determined by spirometry. Importantly, there was no evidence of disease exacerbation related to ALN-RSV01 treatment.
More from Release
Related Categories
FDAStocks Mentioned
-0.26
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
